S. Supiot

Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design

Karim Fizazi, Stéphanie Foulon, Joan Carles et al. · The Lancet · 2022 · 716 citations · Full text

Factorial Design, Urology, × 2 +9

Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer

Charles Catton, Himu Lukka, Chu‐Shu Gu et al. · Journal of Clinical Oncology · 2017 · 683 citations

Radiation Medicine, Nuclear Medicine, Urology +13

Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial

C. Carrié, Ali Hasbini, Guy de Laroche et al. · The Lancet Oncology · 2016 · 356 citations

Urology, Surgical Oncology, Salvage Radiotherapy +8

Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial

Paul Sargos, Sylvie Chabaud, I. Latorzeff et al. · The Lancet Oncology · 2020 · 307 citations · Full text

Surgical Oncology, Urology, Radiation Therapy +8

Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial

C. Carrié, Nicolas Magné, Patricia Burban-Provost et al. · The Lancet Oncology · 2019 · 239 citations · Full text

Surgical Oncology, Urology, Radiation Therapy +8